Get the Daily Brief
Latest Biotech News
Early CRISPR editing shows deep lipid drops... but safety questions linger
Early clinical data from a CRISPR‑based in‑vivo therapy reduced LDL cholesterol and triglycerides dramatically in a small cohort, according to a preliminary report presented at a major cardiology...
SGLT2s broaden kidney care: benefits hold across GFR and albuminuria
A large analysis presented at Kidney Week and published in JAMA found sodium‑glucose cotransporter‑2 (SGLT2) inhibitors improve kidney outcomes across a wide range of glomerular filtration rates...
China clears PacBio long‑read sequencer for clinical use – first global regulatory win
PacBio announced that Berry Genomics obtained National Medical Products Administration (NMPA) Class III approval in China for the Sequel II CNDx system, marking the first regulatory clearance of a...
Qiagen buys Parse Biosciences – single‑cell consolidation accelerates
Qiagen agreed to acquire Parse Biosciences for up to $280 million, folding a high‑throughput single‑cell library prep vendor into a larger molecular diagnostics and sample‑prep infrastructure....
Swiss Rockets licenses CoolMPS... aims to be western NGS instrument maker
Swiss Rockets secured an exclusive license from MGI Tech and Complete Genomics for CoolMPS sequencing chemistry outside Asia‑Pacific, positioning the Basel‑based incubator to enter next‑generation...
CMS launches Medicaid drug pricing model – voluntary international‑reference approach
The Centers for Medicare & Medicaid Services unveiled the GENEROUS payment model to lower outpatient drug spending in Medicaid by negotiating prices linked to selected international benchmarks....
Hi‑C lymphoma assay shows FISH‑replacement potential in clinical labs
Arima Genomics reported early clinical results for its Aventa Hi‑C lymphoma sequencing assay that identified clinically significant gene fusions and rearrangements in FFPE lymphoma samples where...
Patient dies in Intellia CRISPR study — Phase III programs paused
A patient treated with Intellia Therapeutics’ in vivo CRISPR base‑editing therapy nexiguran ziclumeran (nex‑z) for transthyretin amyloidosis with cardiomyopathy (ATTR‑CM) has died after...
Pfizer outbids Novo — $10 billion Metsera takeover sealed
Pfizer won a heated bidding war for obesity‑drug developer Metsera, raising its offer to about $10 billion and outmaneuvering Novo Nordisk. The transaction resolves an aggressive acquisition...
Merck’s oral PCSK9 pill matches injectables: Phase 3 shows deep LDL cuts
Merck presented Phase 3 data showing its once‑daily oral PCSK9 inhibitor produced LDL cholesterol reductions up to 60% in patients already on statins, matching reductions historically seen with...
CRISPR edit cuts LDL and triglycerides in early human study — safety questions remain
A small early‑phase study of a CRISPR‑based gene editing therapy significantly reduced LDL cholesterol and triglycerides in patients with heart disease, according to published data and AHA...
China clears PacBio long‑read sequencer — clinical HiFi sequencing approved
China’s National Medical Products Administration granted Class III medical‑device registration for Berry Genomics’ Sequel II CNDx system using PacBio HiFi long‑read sequencing, marking the first...
Swiss Rockets licenses CoolMPS — western push for MGI tech
Swiss Rockets secured an exclusive license to MGI/Complete Genomics’ CoolMPS sequencing chemistry for regions outside Asia‑Pacific and plans to launch CoolMPS‑based next‑generation sequencers as...
Qiagen to buy Parse Biosciences — single‑cell consolidation deepens
Qiagen agreed to acquire Parse Biosciences for up to $280 million, folding a high‑throughput single‑cell library‑prep platform into a larger corporate portfolio. Parse cofounders and key personnel...
SGLT2s help kidneys broadly — benefit transcends diabetes and GFR bands
Large‑scale analyses presented at Kidney Week and published in JAMA show sodium‑glucose cotransporter‑2 (SGLT2) inhibitors confer renal and cardiovascular benefits across a wide range of estimated...
U.S. drug‑pricing moves: CMS launches Medicaid pricing model — FDA adds priority‑review meds
CMS announced a voluntary five‑year 'GENEROUS' model to negotiate Medicaid outpatient drug prices linked to international benchmarks, inviting manufacturers and states to participate beginning...
New LNP cuts influenza mRNA dose 100‑fold in mice — delivery advance
MIT researchers reported a novel degradable ionizable lipid‑based LNP that delivered an influenza mRNA vaccine in mice at roughly 1/100th the dose of current formulations while maintaining...
Patient dies in Intellia CRISPR trial — FDA puts MAGNITUDE studies on hold
Intellia disclosed that an elderly patient treated with its LNP‑delivered CRISPR candidate nexiguran ziclumeran (nex‑z) died after developing severe liver dysfunction, prompting the company to...
Pfizer clinches Metsera for $10 billion — deal ends Novo fight
Pfizer emerged victorious in the takeover battle for obesity‑drug developer Metsera, agreeing to an increased offer valuing the company at about $10 billion. The late‑stage bid ended a public...
Cholesterol drug race... Merck’s oral PCSK9 and early CRISPR cuts shine
Late‑stage and early‑stage results surfaced this week that intensify competition in lipid‑lowering therapies. Merck reported Phase‑3 data showing its oral PCSK9 inhibitor (enlicitide) cut LDL...